Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024530 (
malaria
)
44,886
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bakakas are native Bantus belonging to the Mbo-Bakossi group, peopling the Cameroon's Littoral region. In the context of a wide bio-anthropological study project focused on the bio-historical processes involved in the areas, 278 adults of both sexes from the villages of Ebone and Bakwat (Bakaka Canton) were investigated for 14 erythrocyte and serum genetic polymorphisms (ACP1, ADA, EsD, GLO, Hb beta, GPX1, CAII, PGM1,
SAHH
, 6-PGD, Hp, Pi, Gc and Tf). With only a few exceptions (Hp and GLO systems), the genetic frequencies of the polymorphisms considered tend to fall within the range of variation known for the subsaharan populations. With reference to the
malaria
endemicity characterizing the Littoral environment, high frequencies for Hb beta*S allele and absence of the ACP1*R 'Negro allele' were recorded. The genetic distances among Bakakas and 14 other Central African populations were also calculated from six genetic loci.
...
PMID:A bio-anthropological study on the Bakakas of Cameroon. 158 May 43
Compounds that specifically inhibit S-adenosylhomocysteine hydrolase (
SAHH
; EC 3.3.1.1) interfere with the proliferation of Plasmodium malarial parasites, but efforts to identify the enzyme directly in parasite extracts have been unsuccessful. Here we report genetic and biochemical evidence for the presence of a gene encoding P. falciparum
SAHH
. The gene is transcribed as a 2.8-kilobase mRNA in erythrocytic stage parasites. Analysis of the open reading frame predicts a 53.9-kDa protein having conserved regions thought to be involved in NAD binding. The cDNA sequence has been incorporated into an Escherichia coli expression construct to confirm the function of the sahh product. Transformed E. coli cells produce a protein with a relative molecular weight of 56,000 which possesses
SAHH
activity as evidenced by the conversion of 3-deazaadenosine to S-3-deazaadenosylhomocysteine. Several amino acid residues that have been suggested to be at the
SAHH
active site in other organisms show nonconserved replacements in P. falciparum, suggesting that some current proposals for the enzyme mechanism may need to be revised. The structural differences between the P. falciparum and mammalian
SAHH
enzymes may foster innovative strategies for drug development against
malaria
.
...
PMID:Plasmodium falciparum S-adenosylhomocysteine hydrolase. cDNA identification, predicted protein sequence, and expression in Escherichia coli. 820 44
The methylation of DNA, RNA, and proteins plays crucial roles in numerous biological processes, including epigenetic control, virus replication, and cell differentiation. In mammals, the rate-limiting step of the S-adenosylmethionine-dependent methylation process is exclusively controlled by S-adenosylhomocysteine (S-AdoHcy) hydrolase (
SAHH
).
SAHH
hydrolyzes S-AdoHcy to adenosine and homocysteine (Hcy) and is therefore a potential therapeutic target for various diseases, including cancer,
malaria
, and viral diseases. However, a simple and highly sensitive assay for the evaluation of
SAHH
activity, particularly for drug discovery, had not yet been developed. Here we present the development of a fluorescence-based assay for the measurement of
SAHH
activity in biological samples. We combined the advantages of the detection of fluorescent thiol groups in Hcy by ThioGlo1 with the S-AdoHcy-driven enzyme-coupled reaction. Our results confirmed the reliability of the proposed assay for the measurement of the
SAHH
activity of purified
SAHH
and showed the potential of this assay for the measurement of the
SAHH
activity of biological samples. Therefore, the proposed
SAHH
activity assay may be utilized in clinical laboratories and in high-throughput screenings for the identification of new
SAHH
inhibitors with potentially beneficial effects on numerous pathologies.
...
PMID:A fluorescence-based assay for the measurement of S-adenosylhomocysteine hydrolase activity in biological samples. 2307 6
The Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase (pfSAHH) enzyme has been considered as a potential chemotherapeutic target against
malaria
due to the amino acid differences found on binding sites of pfSAHH related to human
SAHH
. It has been reported that noraristeromycin and some curcumin derivatives have potential binding with the largest cavity of pfSAHH, which is also related to the binding with Nicotinamide-Adenine-Dinucleotide (NAD) and Adenosine (ADN). Our present work focuses on docking and ADMET studies to select potential inhibitors of pfSAHH. The binding of the selected inhibitor of the PfSAHH active site was analyzed using Molegro Virtual Docker. In this study, curcumin and its derivatives have been found to have higher binding affinity with pfSAHH than noraristeromycin. Seven amino acid residues Leu53, His54, Thr56, Lys230, Gly397, His398 and Phe407 of pfSAHH involved in binding with curcumin, are the same as those for noraristeromycin, which reveals that curcumin and noraristeromycin bind in the same region of pfSAHH. Curcumin has shown a strong interaction with hydrophobic amino acid residues of pfSAHH. Molecular Docking and ADMET predictions suggest that curcumin can be a potent inhibitor of pfSAHH with ability to modulate the target in comparatively smaller dose. Therefore, curcumin is likely to become a good lead molecule for the development of effective drug against
malaria
.
...
PMID:Docking and in silico ADMET studies of noraristeromycin, curcumin and its derivatives with Plasmodium falciparum SAH hydrolase: a molecular drug target against malaria. 2360 35
The human
malaria
parasite Plasmodium falciparum is responsible for the death of more than a million people each year. The emergence of strains of this
malaria
parasite resistant to conventional drug therapy has stimulated the search for antimalarial compounds with novel modes of action. Here the structure-function relationship studies for two Plasmodium proteins are presented. One example is the structural studies for S-adenosyl-L-homocysteine hydrolase from Plasmodium falciparum (PfSAHH) and the other example is those for 1-deoxy-D-xylulose reductoisomerase from Plasmodium falciparum (PfDXR). In the former study, the clue for design of species specific PfSAHH inhibitors was obtained by the structural comparison of the active site of PfSAHH with that of human
SAHH
(HsSAHH). Our study revealed that the inhibitor selectivity depends on the difference of only one amino acid residue in the active site; Cys59 in PfSAHH vs. Thr60 in HsSAHH. In the latter study, the inhibition of PfDXR enzyme by fosmidomycin has proved to be efficient in the treatment of uncomplicated
malaria
in recent clinical trials conducted in Gabon and Thailand. Our crystal structure analyses of PfDXR/inhibitor complexes revealed the molecular basis of fosmidomycin's action in P. falciparum. We expect that the structure-function relationship studies on Plasmodium proteins are useful for developing the more effective antimalarial compounds.
...
PMID:[Structural biology for developing antimalarial compounds]. 2364 94